



Publication on pre-clinical results with SCO-201

Scandion Oncology A/S ("Scandion Oncology") hereby announces that the company has published pre-clinical results with its second drug candidate, SCO-201, for reversal of drug resistance.

ABC transporters are key players in resistance to multiple anti-cancer drugs, leading to cancer treatment failure and cancer-related death. Currently, there are no clinically approved drugs for the reversal of cancer drug resistance caused by ABC transporters. Scandion Oncology has in its pre-clinical study concluded that SCO-201 is a specific, potent, and potentially non-toxic drug candidate for the reversal of ABC transporter mediated resistance in cancer cells.

The results have been published in the international peer reviewed journal *Cells* as part of the Special Issue "Killing Cancer: Discovery and Selection of New Target Molecules" and is available online: <https://www.mdpi.com/2073-4409/9/3/613/pdf>

CSO Jan Stenvang comments

"We are very pleased about the results that we have obtained in our pre-clinical studies with SCO-201. These studies conclude that SCO-201 is a highly promising drug candidate for drug-resistant cancer where overexpression of ABC transporters is a key mechanism of drug resistance. This finding is of great importance, in commercial aspects, and for our future development pipeline."

For further information regarding Scandion Oncology, please contact:

Nils Br nner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

Scandion Oncology A/S is a biotechnology company that addresses and tackles one of the greatest challenges in modern oncology – the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company's leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. In addition to SCO-101 the Company has two other drug candidates, SCO-201 and SCO-301. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.